An open-label study on safety and tolerability of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer

Okamoto, Isamu; Udagawa, Hibiki; Kanda, Shintaro; Han, Tae Hyung; Lakatos, I; Zhang, F.; Okubo, Sumiko; Scripture, Charity D.; Takeda, Masayuki; Akamatsu, Hiroaki; Tamura, Tomohide

doi:10.1093/annonc/mdx386.009

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A phase I trial found that patients with high DLL3 expression in SCLC showed a better response to Rova-T than those with a low DLL3 expression [34]. However, disappointingly, the phase III TAHOE trial has been stopped because the Rova-T group showed a worse OS compared to the control group [35]. But more clinical trials are recruiting participator to investigate Rova-T as maintenance therapy in advanced stage SCLC.…”

Section: Discussionmentioning

confidence: 99%

Potential prognostic value of delta-like protein 3 in small cell lung cancer: a meta-analysis

Chen

Liu

et al. 2020

World J Surg Onc

View full text Add to dashboard Cite

Background: Current researches have revealed that delta-like protein 3 (DLL3) may be related with prognosis in patients with small cell lung cancer (SCLC). However, this finding remains controversial in small cell lung cancer. This meta-analysis was systematically performed to evaluate the prognostic value of DLL3 in SCLC. Methods: The PubMed, EMBASE and Web of Science databases were retrieved to collect the eligible references. Through Stata 15.0 software, we pooled hazard ratios (HR) with 95% confidence intervals (CI) by using random or fixed-effects models to evaluate the association between DLL3 and SCLC survival results. Results: A total of 6 interrelated studies including 645 patients were qualified. After we removed 1 study, the remaining 5 studies including 601 patients were pooled to testify that high expression of DLL3 was an inferior prognostic for patients with SCLC in Asian populations (HR = 1.37, 95% CI = 1.05, 1.69; I 2 = 0.0%, p = 0.000). The pooled results showed that DLL3 might be higher expression in advanced metastasis SCLC in Asian populations (RR = 0.84, 95% CI = 0.71, 0.99; I 2 = 44.7%, p = 0.039). But the expression of DLL3 was not correlated with sex (RR = 1.33, 95% CI = 0.98, 1.80; I 2 = 0.0%, p = 0.064), smoking history (RR = 1.01, 95% CI = 0.58, 1.75; I 2 = 72.1%, p = 0.967) and tumour stage (RR = 0.68, 95% CI = 0.44, 1.05; I 2 = 66.6%, p = 0.081). Conclusions: Our meta-analysis confirms that in Asian populations, high expression of DLL3 was a potential poor prognostic biomarker for SCLC and DLL3 highly expressed in advanced stage SCLC in Asian populations.

show abstract

Section: Discussionmentioning

confidence: 99%